Abstract: The present invention provides a novel method of producing the 12-membered ring macrolide compound 11107D having an antitumor activity by biological transformation. Starting material which is the 12-membered ring macrolide compound 11107B represented by the formula (I) is incubated in the presence of a strain belonging to the genus Mortierella, the genus Streptomyces or the family Micromonosporaceae (for example, Streptomyces sp. AB-1704 strain (FERM BP-8551)), each of which has the ability of transforming the 12-membered ring macrolide compound 11107B into a 11107D substance represented by the formula (II), or a preparation of its cultured myceha and oxygen, and then 11107D substance which is a target material is collected from the treating solution.

Abstract: The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution of Streptomyces sp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it.

Abstract: The present invention provides a method for stabilizing a macrolide compound, and an efficient method for producing the compound. Specifically, it provides a method for stabilizing a macrolide compound, in which a 12-membered ring macrolide compound, such as a compound expressed by the formula (1) and a cyclodextrin are both present, and a method for producing a macrolide compound, in which a cyclodextrin is made to be present in a culture broth of actinomycetes having an ability of producing the macrolide compound.

Abstract: The present invention provides polypeptides that participate in the biosynthesis of the pladienolide macrolide compounds, DNA that encodes these polypeptides and variants of this DNA, transformants that maintain all or a portion of this DNA or variant thereof, and a method of producing the pladienolide macrolide compounds using these transformants. More particularly, it provides an isolated pure DNA that contains at least one region encoding a polypeptide that participates in pladienolide biosynthesis; polypeptide encoded by this DNA; a self-replicating or integrated-replicating recombinant plasmid carrying this DNA; a transformant maintaining this DNA; and a method of producing a pladienolide, characterized by culturing this transformant on culture medium and collecting pladienolide from this culture medium.

Abstract: Compounds represented by the following general formula (I), pharmacologically acceptable salts thereof or hydrates of the same: (I) wherein W represents and R3, R7, R16, R17, R20, R21 and R21? are the same or different and each represents hydrogen, etc. Because of inhibiting angiogenesis and inhibiting the production of VEGF particularly in hypoxia, the compounds (I) are useful as remedies for solid cancer.

Abstract: The present invention provides a method for stabilizing a macrolide compound, and an efficient method for producing the compound. Specifically, it provides a method for stabilizing a macrolide compound, in which a 12-membered ring macrolide compound, such as a compound expressed by the formula (1) and a cyclodextrin are both present, and a method for producing a macrolide compound, in which a cyclodextrin is made to be present in a culture broth of actinomycetes having an ability of producing the macrolide compound.

Abstract: The present invention provides a novel method of producing the 12-membered ring macrolide compound 11107D having an antitumor activity by biological transformation. Starting material which is the 12-membered ring macrolide compound 11107B represented by the formula (I) is incubated in the presence of a strain belonging to the genus Mortierella, the genus Streptomyces or the family Micromonosporaceae (for example, Streptomyces sp. AB-1704 strain (FERM BP-8551)), each of which has the ability of transforming the 12-membered ring macrolide compound 11107B into a 11107D substance represented by the formula (II), or a preparation of its cultured mycelia and oxygen, and then 11107D substance which is a target material is collected from the treating solution.

Abstract: When knitting the sole section and instep section of the toe section, knitting is performed while sequentially decreasing the number of stitches on the small-toe side of the toes by a specified number, and after the number of stitches on the large-toe side has been decreased by a ratio larger than the ratio of decreasing the number of stitches on the small-toe side, the number is increased by the same ratio, and by doing this, on the small-toe side, the side edge section goes toward the tip end and deviates to the inside at a specified ratio, and on the large-toe side, side edge section is nearly a straight line toward the tip end, and by doing this, the shape of the tip end of the toe section protrudes such that it gradually extends to the front of the toes going from the small-toe side to the large-toe side, and that shape is such that it runs along the curve that is obtained by connecting the tip ends of the toes.

Abstract: The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution of Streptomyces sp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it.

Abstract: The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution of Streptomyces sp. Mer.

Abstract: Compounds represented by the following general formula (I), pharmacologically acceptable salts thereof or hydrates of the same: (I) wherein W represents and R3, R7, R16, R17, R20, R21 and R21? are the same or different and each represents hydrogen, etc. Because of inhibiting angiogenesis and inhibiting the production of VEGF particularly in hypoxia, the compounds (I) are useful as remedies for solid cancer.

Abstract: When knitting the sole section and instep section of the toe section, knitting is performed while sequentially decreasing the number of stitches on the small-toe side of the toes by a specified number, and after the number of stitches on the large-toe side has been decreased by a ratio larger than the ratio of decreasing the number of stitches on the small-toe side, the number is increased by the same ratio, and by doing this, on the small-toe side, the side edge section goes toward the tip end and deviates to the inside at a specified ratio, and on the large-toe side, side edge section is nearly a straight line toward the tip end, and by doing this, the shape of the tip end of the toe section protrudes such that it gradually extends to the front of the toes going from the small-toe side to the large-toe side, and that shape is such that it runs along the curve that is obtained by connecting the tip ends of the toes.

Abstract: Asymmetrical hosiery (10) knitted by a hosiery knitting machine, wherein a tip position (G) of a tip top part (14) is positioned nearer to a big toe side (16), characterized in that a first gusset part (22) is knitted nearer to the big toe side (16) of the tip toe section (14) so as to near a shape of a human foot having a big toe thicker and longer than other toes so that bulge of the tip toe section (14) on the big toe side (16) can be made larger than that of a little toe side (18), and that a second gusset part (24) is knitted nearer to the big toe side (16) following the first gusset part (22) so as to extend the big toe side (16) without substantially extending the little toe side (18) of the tip toe section (14).

Abstract: Asymmetrical hosiery (10) knitted by a hosiery knitting machine, wherein a tip position (G) of a tip top part (14) is positioned nearer to a big toe side (16), characterized in that a first gusset part (22) is knitted nearer to the big toe side (16) of the tip toe section (14) so as to near a shape of a human foot having a big toe thicker and longer than other toes so that bulge of the tip toe section (14) on the big toe side (16) can be made larger than that of a little toe side (18), and that a second gusset part (24) is knitted nearer to the big toe side (16) following the first gusset part (22) so as to extend the big toe side (16) without substantially extending the little toe side (18) of the tip toe section (14).

Abstract: A hosiery, whose shape is quite similar to that of a foot of a man and which never presses the big toe, the hosiery includes a cylindrical section; a toe section being forwardly extended from a front end of the cylindrical section, wherein a front tip point of the toe section is located on a big toe side with respect to a center line of the hosiery; and an additional section being formed in the toe section, wherein thickness of the toe section including the additional section is thicker than that of other parts of the toe section and the additional section is located on the big toe side with respect to the center line of the hosiery.

Abstract: A method for coating a core of a small sized motor having a jig or the like by applying a liquid primer forming a primer coat film followed by applying a powder coating using either a friction charging type electrostatic powder gun or an inner charging type electrostatic powder gun. This method prevents rust from forming on the shaft hole and its peripheral portions covered by the jig, and it prevents the deterioration of the insulation coat film on the winding wires upon contact with burrs.

Abstract: A printing apparatus is capable of detecting the end of an ink ribbon and verifying normal mounting of a ribbon cassette. When a portion of ink ribbon sufficient for printing one character is transported, an actuator in the ribbon cassette is rotated by a predetermined amount. The rotating actuator turns on and off a switch. The number of times the switch status is changed is detected. Determining the switch ON-OFF count makes it possible to detect the ink ribbon end and to check for any abnormal winding operation of the ink ribbon. Thus a single switch arrangement permits detection of both the ink ribbon end and an abnormal ink ribbon winding operation that may occur.

Abstract: An indicator needle is provided with a base having a groove having a U-shaped cross section, which groove has an opening in an upper surface thereof and extends in a longitudinal direction of the indicator, and a light transmitting lens which plugs the opening of the upper surface of the base. A plurality of light emitting diodes are arranged in the groove of the base. Base ribs each having a triangular cross section and formed integrally with the base so as to cross the groove of the base are provided in the groove of the base, as well. Light generated from the light emitting diodes directly illuminates the lens, or is reflected by the base ribs to illuminates the same.